The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?

by Philippe Van Wilder
Published 2021-04-01

Advanced Therapy Medicinal Products (ATMP)and exemptions to the Regulation 1394/2007: how confident can we be? An exploratory analysis.

by Philippe eVan Wilder
Published 2012-02-01

The impact of early phase price agreements on prices of orphan drugs

by Mark Nuijten, Philippe Van Wilder
Published 2021-03-01

Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Diso...

by Philippe van Wilder, Irina Odnoletkova, Mehdi Mouline, Esther de Vries
Published 2021-01-01

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations

by Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys
Published 2021-02-01

Factors associated with costs of care in community-dwelling persons with dementia from a third party payer and societal perspective: a cross-sectional study

by S. Vandepitte, L. Van Wilder, K. Putman, N. Van Den Noortgate, S. Verhaeghe, J. Trybou, L. Annemans
Published 2020-01-01

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis

by Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Arnold G. Vulto, Isabelle Huys
Published 2021-04-01

Health-related quality of life in patients with non-communicable disease: study protocol of a cross-sectional survey

by Els Clays, Pauline Boeckxstaens, Delphine De Smedt, Peter Pype, Brecht Devleesschauwer, Lisa Van Wilder, Diego Schrans
Published 2020-09-01

A decade of commitment to hospital quality of care: overview of and perceptions on multicomponent quality improvement policies involving accreditation, public reporting, inspection...

by Astrid Van Wilder, Jonas Brouwers, Bianca Cox, Luk Bruyneel, Dirk De Ridder, Fien Claessens, Kristof Eeckloo, Kris Vanhaecht
Published 2021-09-01

Six years of measuring patient experiences in Belgium: Limited improvement and lack of association with improvement strategies.

by Astrid Van Wilder, Kris Vanhaecht, Dirk De Ridder, Bianca Cox, Jonas Brouwers, Fien Claessens, Dirk De Wachter, Svin Deneckere, Dirk Ramaekers, Else Tambuyzer, Ilse Weeghmans, Luk Bruyneel
Published 2020-01-01

The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data

by Irina Odnoletkova, Gerhard Kindle, Isabella Quinti, Bodo Grimbacher, Viviane Knerr, Benjamin Gathmann, Stephan Ehl, Nizar Mahlaoui, Philippe Van Wilder, Kris Bogaerts, Esther de Vries, in collaboration with the Plasma Protein Therapeutics Association (PPTA) Taskforce
Published 2018-11-01